Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1994 1
1995 2
1996 1
1998 1
2002 1
2003 1
2004 2
2005 6
2006 6
2007 2
2008 2
2009 6
2010 7
2011 5
2012 8
2013 20
2014 11
2015 19
2016 18
2017 11
2018 7
2019 9
2020 7
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

154 results
Results by year
Filters applied: . Clear all
Page 1
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Rogliani P, et al. Pulm Pharmacol Ther. 2016 Oct;40:95-103. doi: 10.1016/j.pupt.2016.07.009. Epub 2016 Jul 29. Pulm Pharmacol Ther. 2016. PMID: 27481628 Review.
BACKGROUND: The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year. Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received only a conditional recommendation for use and, thus, to date no drugs are stro …
BACKGROUND: The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year. Pirfenidone and nintedanib …
Japanese guideline for the treatment of idiopathic pulmonary fibrosis.
Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Homma S, et al. Respir Investig. 2018 Jul;56(4):268-291. doi: 10.1016/j.resinv.2018.03.003. Epub 2018 Jul 3. Respir Investig. 2018. PMID: 29980444 Review.
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of idiopathic interstitial pneumonia. ...
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20. N Engl J Med. 2012. PMID: 22607134 Free PMC article. Clinical Trial.
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. ...CONCLUSIONS: Increased risks of death and hospitalization were observed in patients with …
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for i
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
Sakamoto S, Kataoka K, Kondoh Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S; Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Sakamoto S, et al. Eur Respir J. 2021 Jan 5;57(1):2000348. doi: 10.1183/13993003.00348-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32703779 Clinical Trial.
BACKGROUND: A randomised controlled trial in Japan showed that inhaled N-acetylcysteine monotherapy stabilised serial decline in forced vital capacity (FVC) in some patients with early idiopathic pulmonary fibrosis (IPF). ...CONCLUSIONS: Combina …
BACKGROUND: A randomised controlled trial in Japan showed that inhaled N-acetylcysteine monotherapy stabilised serial decline …
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE. Canestaro WJ, et al. Chest. 2016 Mar;149(3):756-66. doi: 10.1016/j.chest.2015.11.013. Epub 2016 Jan 13. Chest. 2016. PMID: 26836914 Review.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung disease of unknown origin. ...CONCLUSIONS: Although two treatments have been approved for IPF on the basis of reduced decline in pulmonary func …
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung disease of …
Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K, McCool R, Glanville J, Edwards SC, Gsteiger S, Daigl M, Fisher M. Fleetwood K, et al. J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S5-S16. doi: 10.18553/jmcp.2017.23.3-b.s5. J Manag Care Spec Pharm. 2017. PMID: 28287346 Review.
BACKGROUND: The antifibrotics pirfenidone and nintedanib are both approved for the treatment of idiopathic pulmonary fibrosis (IPF) by regulatory agencies and are recommended by health technology assessment bodies. Other treatments such as N-acetylc
BACKGROUND: The antifibrotics pirfenidone and nintedanib are both approved for the treatment of idiopathic pulmonary fibros
Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.
Newton CA, Zhang D, Oldham JM, Kozlitina J, Ma SF, Martinez FJ, Raghu G, Noth I, Garcia CK. Newton CA, et al. Am J Respir Crit Care Med. 2019 Aug 1;200(3):336-347. doi: 10.1164/rccm.201809-1646OC. Am J Respir Crit Care Med. 2019. PMID: 30566847 Free PMC article. Clinical Trial.
Rationale: Immunosuppression was associated with adverse events for patients with idiopathic pulmonary fibrosis (IPF) in the PANTHER-IPF (Evaluating the Effectiveness of Prednisone, Azathioprine and N-Acetylcysteine in Patients with IPF) clinica …
Rationale: Immunosuppression was associated with adverse events for patients with idiopathic pulmonary fibrosis (IPF) i …
The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, Maurer O, Heinemann S, Costabel U, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells A, Vasakova M, Pesci A, Sofia M, Klepetko W, Seeger W, Drakopanagiotakis F, Crestani B. Guenther A, et al. Respir Res. 2018 Jul 28;19(1):141. doi: 10.1186/s12931-018-0845-5. Respir Res. 2018. PMID: 30055613 Free PMC article.
At the time of inclusion in the eurIPFreg, FVC was 68.4% 22.6% of predicted value, DLco ranged at 42.1% 17.8% of predicted value (mean value SD). Signs of pulmonary hypertension were found in 16.8%. Steroids, immunosuppressants and N-Acetylcysteine declined s …
At the time of inclusion in the eurIPFreg, FVC was 68.4% 22.6% of predicted value, DLco ranged at 42.1% 17.8% of predicted value (mean value …
Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Sun T, Liu J, Zhao W. Sun T, et al. Medicine (Baltimore). 2016 May;95(19):e3629. doi: 10.1097/MD.0000000000003629. Medicine (Baltimore). 2016. PMID: 27175674 Free PMC article. Review.
There are a number of conflicting reports describing the clinical outcomes of using N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis. We have, therefore, performed a meta-analysis to evaluate the efficacy of N-acetyl
There are a number of conflicting reports describing the clinical outcomes of using N-acetylcysteine for the treatment of i
Metformin attenuates lung fibrosis development via NOX4 suppression.
Sato N, Takasaka N, Yoshida M, Tsubouchi K, Minagawa S, Araya J, Saito N, Fujita Y, Kurita Y, Kobayashi K, Ito S, Hara H, Kadota T, Yanagisawa H, Hashimoto M, Utsumi H, Wakui H, Kojima J, Numata T, Kaneko Y, Odaka M, Morikawa T, Nakayama K, Kohrogi H, Kuwano K. Sato N, et al. Respir Res. 2016 Aug 30;17(1):107. doi: 10.1186/s12931-016-0420-x. Respir Res. 2016. PMID: 27576730 Free PMC article.
BACKGROUND: Accumulation of profibrotic myofibroblasts in fibroblastic foci (FF) is a crucial process for development of fibrosis during idiopathic pulmonary fibrosis (IPF) pathogenesis, and transforming growth factor (TGF)-beta plays a key regulatory …
BACKGROUND: Accumulation of profibrotic myofibroblasts in fibroblastic foci (FF) is a crucial process for development of fibrosis dur …
[Idiopathic pulmonary fibrosis].
Cottin V, Cordier JF. Cottin V, et al. Presse Med. 2008 Nov;37(11):1581-90. doi: 10.1016/j.lpm.2008.01.024. Epub 2008 May 16. Presse Med. 2008. PMID: 18486432 Review. French.
Idiopathic pulmonary fibrosis is a chronic disorder characterized histopathologically by a pattern of usual interstitial pneumonia, with heterogeneous and mutilating interstitial fibrosis with foci of proliferating fibroblasts, honeycomb lung, and litt
Idiopathic pulmonary fibrosis is a chronic disorder characterized histopathologically by a pattern of usual interstitia
Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
Rushworth GF, Megson IL. Rushworth GF, et al. Pharmacol Ther. 2014 Feb;141(2):150-9. doi: 10.1016/j.pharmthera.2013.09.006. Epub 2013 Sep 28. Pharmacol Ther. 2014. PMID: 24080471 Review.
N-acetyl-l-cysteine (NAC) has long been used therapeutically for the treatment of acetaminophen (paracetamol) overdose, acting as a precursor for the substrate (l-cysteine) in synthesis of hepatic glutathione (GSH) depleted through drug conjugation. Ot
N-acetyl-l-cysteine (NAC) has long been used therapeutically for the treatment of acetaminophen (paracetamol) overdose,
Longitudinal Changes in Clinical Features, Management, and Outcomes of Idiopathic Pulmonary Fibrosis. A Nationwide Cohort Study.
Moon SW, Kim SY, Chung MP, Yoo H, Jeong SH, Kim DS, Song JW, Lee HL, Choi SM, Kim YW, Kim YH, Park CS, Park SW, Park JS, Jegal Y, Lee J, Uh ST, Kim TH, Lee JH, Kim YH, Shin B, Lee HK, Yang SH, Lee H, Kim SH, Lee EJ, Choi HS, Shin H, Park YB, Shin JW, Park MS. Moon SW, et al. Ann Am Thorac Soc. 2021 May;18(5):780-787. doi: 10.1513/AnnalsATS.202005-451OC. Ann Am Thorac Soc. 2021. PMID: 33270528 Clinical Trial.
Rationale: In recent decades, diagnosis and treatment recommendations for idiopathic pulmonary fibrosis (IPF) have changed. In Korea, the average life expectancy has increased, unmet healthcare needs have been reduced, and the number of computed tomographic e …
Rationale: In recent decades, diagnosis and treatment recommendations for idiopathic pulmonary fibrosis (IPF) have chan …
Is N-acetylcysteine effective in the treatment of pulmonary fibrosis?
Jeldres Pulgar A, Labarca G. Jeldres Pulgar A, et al. Medwave. 2016 Sep 29;16(Suppl3):e6555. doi: 10.5867/medwave.2016.6555. Medwave. 2016. PMID: 27689534 English, Spanish.
Idiopathic pulmonary fibrosis is a progressive chronic respiratory disease that in final stages carries high mortality. ...We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded N-
Idiopathic pulmonary fibrosis is a progressive chronic respiratory disease that in final stages carries high mortality.
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.
Staitieh BS, Renzoni EA, Veeraraghavan S. Staitieh BS, et al. Ann Med. 2015 Mar;47(2):100-5. doi: 10.3109/07853890.2014.991751. Epub 2015 Jan 22. Ann Med. 2015. PMID: 25613169 Free PMC article. Review.
Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic disease of the lung of unknown etiology that affects approximately 150,000 patients in the United States. ...Historically, the default therapy for IPF was a combination of prednisone, N
Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic disease of the lung of unknown etiology that affe
154 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page